The TT genotype of the C-344T polymorphism in the 5 0 regulatory region of the aldosterone synthase gene (CYP11B2) has been associated with hypertension (HT), cardiac hypertrophy, higher aldosterone levels in plasma and adrenal tissue, and aldosterone metabolites in urine, increased aldosterone to renin ratios and HT. 1 We investigated possible associations of the CYP11B2 C-344T polymorphism with survival and neurohormonal profiles following acute myocardial infarction (MI). Univariate and multivariate analysis demonstrated a positive association of the TT genotype with survival (P ¼ 0.010) and an interaction between antihypertensive treatment and genotype-influenced survival.
Aldosterone production in adrenal tissue is controlled by the regulated transcription of CYP11B2. 2 Several CYP11B2 polymorphisms have been investigated, but studies have concentrated on the C-344T polymorphism. The transcription regulatory factor SF-1 binds the CYP11B2 gene promoter region and is affected by the C-344T polymorphism, 3 but controversy remains about the significance of this to expression of aldosterone synthase. 4 C-344T genotype was associated with systolic blood pressure and aldosterone to renin ratio in 437 elderly subjects. 5 Following oral sodium load TT and CT hypertensives exhibited greater suppression of serum aldosterone than CC hypertensives. 6 These studies suggest complex gene-environment interactions influence CYP11B2 gene expression, which may explain some of the contradictory associations reported in the literature.
CYP11B2 genotypes were obtained from 902 patients from the Christchurch Post-MI study. 7 Overall genotype frequencies were CC 19.0%, CT 53.1% and TT 27.9%, which conformed to the expected Hardy-Weinberg equilibrium (P ¼ 0.998) and agreed with results of studies of predominantly European populations. 3 The investigation, approved by the Canterbury Ethics Committee, conforms to the principles of the Declaration of Helsinki. Patients were assigned to one of four self-identified ethnic groups: European, Maori, Non-European/ Non-Maori and Not-Stated. All participating patients provided written, informed consent. Genomic DNA was assayed for the CYP11B2 C-344T polymorphism as described previously. 3 Quality control included positive control samples in each batch of assays and reassaying 10% of samples, randomly selected, with 100% concordance.
Patients from all ethnic groups were included in primary statistical analyses. To increase confidence that the results reported were not artifacts due to potential ethnic admixture of the population, P-values for pooled European (n ¼ 712) and Not-Stated (n ¼ 105) (E&NS) groups are also presented. The NS group appears to consist of European patients who did not report their ethnicity, as the genotype frequencies of the European and NS groups are highly non-significantly different for seven polymorphisms from diverse loci in the genome (Supplementary Table 1 ). The T allele was nonsignificantly more common in the Maori members of the cohort than those of European ethnicity (Maori, n ¼ 18, CC 11.1%, CT 44.4%, TT 44.4%; European n ¼ 712, CC 18.3%, CT 53.9%, TT 27.8%; P ¼ 0.285; Maori vs E&NS (n ¼ 817), P ¼ 0.255). Patients of European ethnicity were stratified by their birthplace (New Zealand or elsewhere), and genotypeassociated differences in survival, antecedent HT and previous MI were similar to those found in the full cohort (data not shown).
Patients were followed for up to 6 years. Patients from this cohort with antecedent HT had increased all-cause mortality after their index MI admission compared to those normotensive before the index admission. 8 We hypothesized a proportion of this antecedent HT was attributable to variation at the CYP11B2 C-344T polymorphism 9 and thus an association of the T-allele with poorer outcome after MI was likely. Patients with TT genotype had a higher incidence of a history of HT (n ¼ 871, CC 34.6%, CT 36.4%, TT 45.0%, P ¼ 0.043; E&NS n ¼ 789, P ¼ 0.035) and trended towards more previous MI (n ¼ 849, CC 13.5%, CT 17.8%, TT 22.5%, P ¼ 0.074; E&NS n ¼ 767, P ¼ 0.068) compared to other genotype groups. Exploratory stratification by gender revealed associations with history of HT and previous MI were more pronounced in males (HT in males, n ¼ 681, CC 28.7%, CT 33.5%, TT 46.1%, P ¼ 0.002, E&NS n ¼ 613, P ¼ 0.001; previous MI in males, n ¼ 665, CC 13.7%, CT 17.7%, TT 24.7%, P ¼ 0.034, E&NS n ¼ 597, P ¼ 0.036).
Plasma samples for neurohormonal measurements (Supplementary Table 2 Table 3 ).
Despite association with higher rates of HT and previous MI and raised BNP levels the TT genotype group survived longer after the index MI. This finding is somewhat counterintuitive. There was no difference in ACE inhibitor or b-blocker treatment at index MI discharge between genotype groups (Supplementary Table 2 ), so the TT group were not more heavily medicated due to their risk profile. However, the association of genotype with survival was influenced by the patients' drug treatment regime. For patients untreated with ACE inhibitors, survival in the CT genotype group was significantly worse than CC or TT patients (P ¼ 0.028) and similarly with b-blockers (P ¼ 0.040) (data not shown). Only the CT genotype group had significantly improved survival following b-blocker treatment (P ¼ 0.007), while survival rates were similar irrespective of b-blocker treatment in the remaining patients (CC, P ¼ 0.566. TT, P ¼ 0.649) (Figure 1b) . b-Blocker treatment has been shown to lower circulating aldosterone levels 10 and in the CT genotype group b-blocker treatment may have lowered aldosterone levels into a range with positive effects on survival.
In the absence of plasma or urine aldosterone measurements, our data cannot clarify the association of CYP11B2 genotype with aldosterone levels, and if in the TT group this contributed to the observed association with survival. Elevated levels of aldosterone might be expected in the TT subgroup, given their higher rates of HT and previous MI, which might exacerbate post-MI cardiac remodelling and fibrosis. However, at least one study has found TT homozygotes to have the lowest plasma aldosterone levels of the three C-344T genotype groups in a hypertensive cohort. 11 It may be that our TT genotype group reacted positively to environmental or interventional factors, for example b-blocker treatment, promoting favourable influences on cardiac remodelling and improved survival. Association studies of outcome after acute MI and CYP11B2 genotype have not been reported in detail previously. However, the Kaplan-Meier survival curve in Figure 1a is similar to one in a report of 354 African American heart failure patients and describes C-344T genotype-dependent responses to drug therapy. 12 In summary, CYP11B2 C-344T genotype is associated with antecedent HT in this post-MI cohort. The TT genotype group had higher baseline levels of BNP, a marker of cardiac dysfunction. Genotype was a predictor of survival in this cohort, independent of established predictors. Anti-hypertensive treatment with ACE inhibitors and b-blockers appears to interact with CYP11B2 genotype to influence survival. Characterisation of such pharmacogenomic associations has potential in developing personalized treatment strategies.
